Neurology
Alzheimer's Disease
Expert Roundtables Podcast: The Importance of Amyloid-β From the Diagnosis of Alzheimer’s Disease to Its Treatment
Advances in biomarker technology now allow for the earlier and more accurate detection of amyloid pathology. With the recent US Food and Drug Administration (FDA) approvals of amyloid-β (Aβ)–targeting therapies, clinicians are entering a new era of disease-modifying treatment that raises important questions about patient selection, timing, and long-term outcomes. Listen to today’s podcast to learn more.
Parent C, Rousseau LS, Predovan D, Duchesne S, Hudon C. Longitudinal association between ß-amyloid accumulation and cognitive decline in cognitively healthy older adults: a systematic review. Aging Brain. 2023;3:100074. doi:10.1016/j.nbas.2023.100074
Pokrzyk J, Kulczyńska-Przybik A, Guzik-Makaruk E, Winkel I, Mroczko B. Clinical importance of amyloid beta implication in the detection and treatment of Alzheimer’s disease. Int J Mol Sci. 2025;26(5):1935. doi:10.3390/ijms26051935
Sims JR, Zimmer JA, Evans CD, et al; TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527. doi:10.1001/jama.2023.13239
Thakor VS, Tyagi A, Lee JM Jr, Coffman F, Mittal R. Alois Alzheimer (1864-1915): the father of modern dementia research and the discovery of Alzheimer’s disease. Cureus. 2024;16(10):e71731. doi:10.7759/cureus.71731
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948
